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MyocilinMutations in the myocilin gene (MYOC) account for most cases of autosomal dominant juvenile-onset
open-angle glaucoma (JOAG), an earlier and more severe form of POAG. We accessed seven members of a
Brazilian JOAG family by clinical and molecular investigation. Four out of seven family members were diag-
nosed with JOAG. All of these patients presented high intraocular pressure and two of them were bilaterally
blind. The disease onset varied from 20 to 30 years old. There was a nine-year-old family member who had
not yet manifested the disease, although he was also a carrier of the mutation. Ophthalmologic examination
included: evaluation of the visual ﬁeld and optic disc, intraocular pressure measurement, and gonioscopy.
The three exons and intron/exon junctions of the MYOC gene were screened for mutations through direct
sequencing of PCR-ampliﬁed DNA fragments. Mutation screening revealed an in-frame mutation in the
third exon of the MYOC gene: an insertion of six nucleotides between the cDNA positions 1187 and 1188
(c.1187_1188insCCCAGA, p.D395_E396insDP). This mutation presented an autosomal dominant pattern of
inheritance, segregating with the disease in four family members for three generations, and it was absent
in 60 normal controls. We also performed a computational structure modeling of olfactomedin-like domain
of myocilin protein and conducted in silico analysis to predict the structural changes in the myocilin protein
due to the presence of the mutation. These ﬁndings may be important for future diagnosis of other
presymptomatic family members, as well as for the increase of the panel ofMYOCmutations and their effects
on phenotype.
© 2013 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Glaucoma is a heterogeneous group of optic neuropathies and is
the leading cause of irreversible blindness worldwide (Fan et al.,
2006; Ray et al., 2003; Shields et al., 1996). Primary open-anglecular pressure; JOAG, juvenile-
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vier OA license.glaucoma (POAG) is the most common form of glaucoma, and is
characterized by slow progression of optic disc atrophy, with corre-
sponding loss of peripheral visual ﬁeld and characteristic excavated
appearance of the optic disc (Quigley and Vitale, 1997). It has been
estimated that approximately 58.6 million people worldwide will be
affected by the disease by the year 2020 (5.9 million will be affected
bilaterally) (Quigley and Broman, 2006). The increase of intraocular
pressure (IOP) is often associated with POAG; therefore, it is consid-
ered a major risk factor (Quigley and Vitale, 1997; Wiggs et al., 1996).
Although the prevalence of POAG increases with age, a subgroup
of patients is diagnosed with a relatively rare form of the disease,
juvenile-onset open-angle glaucoma (JOAG). JOAG has an early
onset, but the age limitation between the adult and juvenile onset is
controversial. Nowadays, it is commonly considered that JOAG mani-
fests between 3 and 35 years old and the initiation of the disease after
this age is categorized as POAG (adult onset). In many cases, JOAG
Table 1
Forward (F) and reverse (R) primers used in the polymerase chain reaction and direct
sequencing of the MYOC gene, their annealing temperature and product size.
Exon Primer sequence (5′–3′) Annealing temperature
(°C)
Product size
(bp)
1 (F) GGTGCATAAATTGGGATGTTC 62.0 999
1 (R) TTGTGCTAGCTGTGCAGTCTC 62.0 999
2 (F) AACATAGTCAATCCTTGGGCC 61.0 346
2 (R) GAGAGTTCTGTTCCTCTTCTCCTC 61.0 346
3a (F) GATTTGTCTCCAGGGCTGTC 65.0 916
3a (R) GCTTGGAGGCTTTTCACATC 65.0 916
3b (F) TCTGTGGCACCTTGTACACC 62.0 841
3b (R) CCACCTTTAACATCCTGCAATC 62.0 841
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mostly considered a complex genetic disease (Wiggs et al., 1996).
JOAG patients typically have high IOP, as well as a frequent need for
surgical treatment (Johnson et al., 1993; Wiggs et al., 1995).
Until now, 17 chromosomal loci have been linked to POAG and/or
JOAG by linkage analysis (GLC1A to GLC1Q) (Allingham et al., 2005;
Baird et al., 2005; Fingert et al., 2011; Lin et al., 2008; Monemi et al.,
2005; Pang et al., 2006; Pasutto et al., 2009; Porter et al., 2011;
Sarfarazi et al., 1998; Shefﬁeld et al., 1993; Stoilova, 1996;
Suriyapperuma et al., 2007; Trifan et al., 1998; Wang et al., 2006;
Wiggs et al., 2004; Wirtz et al., 1997, 1999). The myocilin gene
(MYOC) (region 1q23–q24, GLC1A locus), described in 1997 by
Stone et al. (1997), was the ﬁrst gene linked with JOAG. The myocilin
protein, encoded by theMYOC gene, is a glycoprotein with 504 amino
acids and a signal peptide for secretion, a leucine zipper within an
N-terminal myosin-like domain, and a C-terminal olfactomedin-like
domain (Ortego et al., 1997). The majority (about 85%) of more
than 80 missense or nonsense mutations already found in the MYOC
gene was described in the olfactomedin-like domain, the most con-
served protein domain (www.myocilin.com; Hewitt et al., 2008).
Myocilin can form dimers and multimers, and it is believed that this
protein participates in the formation of the extracellular matrix, al-
though its function has not yet been elucidated (Fautsch and
Johnson, 2001; Jacobson et al., 2001).
Data from in vitro and in vivo studies have indicated that some
mutant myocilin isoforms are not secreted, but are rather retained
in the endoplasmic reticulum (ER) of the trabecular meshwork cells,
causing reticulum stress and apoptosis of these cells (Jacobson et al.,
2001; Joe et al., 2003; Liu and Vollrath, 2004). Different sensitivities
to oxidative stress may be dependent of the type of MYOC mutation.
Cells in culture expressing the p.Y437H mutant were more sensitive
to apoptosis secondary to induction of oxidative stress than the
p.I477N mutant (Joe and Tomarev, 2010). The increased level of oxi-
dative stress-protective proteins as well as the increased level of
pro-apoptotic protein, CHOP, were observed in transgenic mice ex-
pressing p.Y437H MYOC mutation and glaucomatous phenotype (Joe
and Tomarev, 2010; Zhou et al., 2008). Also, apoptosis can be caused
by aggregation of myocilin in the ER that activates unfolded protein
response, an evolutionarily conserved stress pathway (Carbone
et al., 2009). Myocilin is also capable of interacting with various
other proteins such as Optimedin (Torrado et al., 2002), Fibronectin
(Ueda et al., 2002), α1-Syntrophin (Joe et al., 2012), and some simi-
larities between mechanisms of action of Wnt proteins and myocilin
have been demonstrated (catenin-independent mechanism) (Kwon
and Tomarev, 2011). Besides, myocilin may act as non-canonical
Wnt signaling agent, inducing the formation of stress ﬁbers (Kwon
et al., 2009).
MYOC gene mutations are present in 8% to 36% of JOAG cases and
3% to 4% of POAG cases (Fingert, 2011). Although there is a relatively
low contribution of MYOC gene mutations to the etiology of POAG,
the high prevalence of this disease makes them the most important
cause of blindness with a molecular basis (Stone et al., 1997). The im-
portance of recognizing individuals with POAG carrying MYOC muta-
tions has been transformed into the proposal for new therapeutic
approaches, including the use of chemical chaperones such as
Sodium 4-phenylbutarate (PBA) and the regulation of chaperones
with selective inhibition of Glucose-regulated protein 94 (Grp94)
(Suntharalingam et al., 2012; Zode et al., 2012). Besides, as the gain
of function, rather than haploinsuﬁciency, is the mechanism sug-
gested for the development of glaucoma associated withMYOCmuta-
tions, the evaluation of new disease-causing variants is important in
helping to clarify their pathophysiology.
In this paper, we describe a novel in-frame mutation in the MYOC
gene segregating with JOAG in three generations of a Brazilian family.
In addition, we conducted in silico analyses to better understand the
effects of the mutation in the protein.2. Material and methods
2.1. Patient selection
Seven members belonging to a Brazilian family with European an-
cestry from Paraná, a state in the south region of Brazil, were recruited
in the Glaucoma Service at the Clinical Hospital, University of Campinas,
where the clinical analysis was carried out. Ophthalmic examination in-
cluded IOPmeasurement bymeans of applanation tonometry; slit-lamp
biomicroscopy and gonioscopy; evaluation of the optic disc with a
78-diopter lens; and automated perimetry (Humphrey System 24.2;
Zeiss-Humphrey-Zeiss Systems, Dublin, CA, USA). Ocular history was
obtained by interview, including the age at diagnosis of glaucoma, and
clinical and surgical treatment. Diagnosis of JOAG was based on the
presence of at least two of the following characteristics: (1) IOP above
21 mmHg; (2) optic disc changes, including thinning of the neuroretinal
rim, hemorrhage, notch, cup-to-disc ratio greater than 0.7, or asymme-
try of the cup-to-disc ratio greater than 0.2; and (3) glaucomatous visual
ﬁeld defect, deﬁned as a corrected pattern standard deviation outside
the 95% normal limits or a glaucoma hemiﬁeld test result outside the
99% limits. The control group consisted of 60 individuals of varying
ethnicities, mostly white, from different regions of the country, also
recruited in the Glaucoma Service at the Clinical Hospital, University
of Campinas, according to the following criteria: absence of any form
of glaucoma; absence of family history of glaucoma or blindness of un-
known cause; IOPs lower than 15 mmHg; cup-to-disc ratio lower than
0.4; and older than 50 years of age. This study was approved by the re-
search ethics committee of the Faculty ofMedical Sciences, University of
Campinas. The participating subjects gave informed consent, in agree-
ment with the principles enunciated in the Declaration of Helsinki.
2.2. Mutation screening
Whole blood was collected from affected and unaffected family
members and normal controls. Genomic DNA was extracted using the
phenol/chloroform method (Sambrook et al., 1989) and the DNAs
were precipitated with absolute ethanol. The three coding regions and
intron/exon junctions of the MYOC gene were ampliﬁed by PCR, pre-
pared with 40 to 100 ng of DNA template, 20 pmol of each forward
and reverse primer (Table 1), 200 pmol of each dideoxynucleotide,
1× enzyme buffer (10× buffer: 200 mM Tris–HCl pH 8.4, 500 mM
KCl), 0.5 U of Taq DNA polymerase (InvitrogenTM Life Technologies,
Carlsbad, CA, USA), and ultrapure water to complete the ﬁnal volume
of 25 μL. The conditions of ampliﬁcation were the same for all three
exons of theMYOC gene, except for the annealing temperature, as spec-
iﬁed in Table 1: initial denaturation at 95 °C for 5 min, followed by
35 cycles at 95 °C for 1 min, annealing of primers in speciﬁc tempera-
ture for each region for 45 s, and extension at 72 °C for 90 s, ending
with additional extension at 72 °C for 7 min. Both strands of the
MYOC gene were screened for sequence alterations by direct sequenc-
ing, with BigDye Terminator Cycle Sequencing Kit v3.1® (Applied
Biosystems Inc., Foster City, CA, USA) and submitted to electrophoresis
Fig. 1. Pedigree of the studied Brazilian family. The c.1187_1188insCCCAGA mutation
in the myocilin gene segregates with the disease in three generations (individuals
II-3, III-1, IV-1, and IV-4). The red arrow indicates the proband.
52 C.A. Braghini et al. / Gene 523 (2013) 50–57in the ABI Prism 3700 DNA Analyzer automated sequencer (Applied
Biosystems Inc., Foster City, CA, USA). The primers used for PCR and di-
rect sequencing were chosen based on the gene sequence deposited in
GenBank (OMIM ⁎601652) and are depicted in Table 1. Sequencing data
were analyzed through the FinchTV program (Geospiza, Seattle, WA,
USA) and BLAST at the NCBI server.
2.3. In silico analyses
To verify the level of conservation of the region where the mutation
was detected among the species, the sequence of normal human
myocilin was compared with myocilin of other species, using the
program ClustalW for multiple sequence alignment (free access)
(Thompson et al., 1994). Structural analysis was performed by ﬁrst ver-
ifying the existence of solved structures with homologous sequences to
myocilin olfactomedin-like domain (residues 235 to 504) with BLASTp
searches against PDB database. As there were no signiﬁcant hits, an
alternative modeling procedure was employed by using the threading
software I-TASSER (Zhang, 2007). The best ranked model according to
I-TASSER Z-score resembled the folding of a protein whose structure
is described in the PDB ﬁle 2zw9.pdb and was selected for further opti-
mization. Jpred (Cuff et al., 1998) and PSIPRED (Buchan et al., 2010)
were used to predict the type, extension and localization of secondary
structure elements of olfactomedin domain because initial quality as-
sessment of I-TASSER model indicated residues located in prohibited
Ramachandran plot areas. This indication of secondary structure ele-
ments was then used as a set of restraints to a newmodeling procedure
performed by MODELLER 9v11 software (Sali and Blundell, 1993)
which used the I-TASSER output as a template to generate improved
models. As another restraint, a disulﬁte bridge between Cys245 and
Cys433 was introduced (in accordance with experimental evidences
(Nagy et al., 2003)). Obtained models were ranked by Modeller DOPE
score and Ramachandran plot analysis. The best ranked model was ini-
tially reﬁned using YASARA: the system containing the protein
structure immersed in a box with water molecules (solvent) was opti-
mized via energy minimization and molecular dynamics for 500 ps
(using the macro md_reﬁne). By this procedure any remaining steric
clashes were eliminated. Molecular dynamics simulation used the
AMBER03 force ﬁeld and all other parameter values were set to the
same values as in the original macro. The resulting structure selected
as the one with the minimal energy in the molecular dynamics tra-
jectory was then subjected to additional quality assessment using
Prosa-Web (Wiederstein and Sippl, 2007), space-clash analysis and
Ramachandran plot from STING platform and its Java Protein Dossier
(Neshich et al., 2004, 2006). The p.D395_E396insDP and P370L muta-
tions were introduced in the previously obtained model for wild type
structure by homology modeling followed by molecular dynamics re-
ﬁnement via YASARA. The wild type and mutant structures were ana-
lyzed using STING Millennium (BlueStar STING) (Neshich et al., 2003)
and electrostatic surface maps were created employing PyMOL
(DeLano, 2002). Accessible surface areas were calculated using the soft-
ware SurfV (Sridharan et al., 1992). The structures were analyzed for
hydrophobicity at exposed surface through SHI algorithm (Surface Hy-
drophobicity Index) (Neshich et al., unpublished results).
3. Results
3.1. Phenotypic studies
ABrazilian family harboring JOAG in three generationswith an auto-
somal dominant inheritance pattern was identiﬁed (Fig. 1). Individual
II-3 was subjected to two trabeculectomies, but was bilaterally blind
at age 67. The proband, his son (III-1), also lost the vision in both eyes
at age 40, presenting visual acuity of 20/25 and 20/60 with tubular
visual ﬁeld (less than 10°). He underwent three trabeculectomies in
both eyes for IOP control, but still needs to use prostaglandin analogsto maintain IOP close to 10 mmHg. One of the proband's daughters,
member IV-1, was diagnosed with JOAG at the age of 20. Since then,
she has been using three medications for IOP control. However, due to
two pregnancies, the clinical treatment was interrupted and her IOP
rose to 30 and 28 mmHg in the right eye (RE) and left eye (LE), respec-
tively. Her visual acuity is 20/20 in both eyes and the visual ﬁeld pre-
sents with superior arcuate scotoma in RE and incomplete superior
arcuate scotoma in the LE with vertical cup-to-disc ratios of 0.9 and
0.7 in the RE and LE, respectively. At this moment, IOP is under control
(12 mmHg) with maximum topical medication. The other two daugh-
ters, individuals IV-2 and IV-3, have no symptom of glaucoma
(Table 2), but individual IV-4 was diagnosed as ocular hypertensive at
22 years of age, with IOPs of 22 and 23 mmHg in the RE and LE, respec-
tively. Due to his low age and the presence of risk factors for glaucoma,
including the rise in IOP and family history of glaucoma, clinical treat-
ment was initiated. Nowadays, his IOP is between 15 and 18 mmHg in
both eyes, controlled with prostaglandin analogs and beta-blocker.
The visual ﬁeld remains unaltered and the vertical cup-to-disc ratio is
0.2 and 0.3. All members of this family presented with wide-open
angle at gonioscopy, allowing visualization of ciliary band. All affected
members presented with high IOP and severe disease (except individu-
al IV-4, who is clinically controlled) that required intensive clinical
treatment; in the older members of the family, more than one surgical
intervention was necessary for IOP control. Mean age at diagnosis of
glaucoma was 25.25, ranging from 20 to 30, characterizing the disease
as JOAG. The clinical data on the familymembers are depicted in Table 2.3.2. Genotypic studies
By direct sequencing, a new in-frame mutation, an insertion of six
nucleotides between the cDNA positions 1187 and 1188 (c.1187_
1188insCCCAGA) in the MYOC gene was identiﬁed, segregating in
four individuals with the disease (II-3, III-1, IV-1, IV-4) from three
generations of that particular Brazilian family (Fig. 2). This insertion
Table 2
Clinical features of the Brazilian family members according to the presence/absence of the mutation.
ID Family member Diagnosis Mutation Age/age diag. (years) Highest IOP RE (mmHg) Highest IOP LE (mmHg) CD ratio RE CD ratio LE Surgeries/medication
II-3 Father JOAG Yes 77/30 34.00 34.00 1.00 1.00 2/1
III-1 Proband JOAG Yes 48/29 42.00 47.00 1.00 1.00 3/2
IV-1 Daughter JOAG Yes 23/20 30.00 28.00 0.90 0.70 –/3
IV-2 Daughter Normal No 12/– 16.00 16.00 0.20 0.20 –/–
IV-3 Daughter Normal No 21/– 14.00 14.00 0.20 0.20 –/–
IV-4 Son JOAG Yes 27/22 22.00 23.00 0.20 0.30 –/2
V-1 Grandson Normal Yes 9/– No data No data 0.30 0.30 –/–
Abbreviations: ID = identity, Age Diag. = age at diagnosis, Highest IOP: highest intraocular pressure; CD ratio: cup-to-disc ratio; RE = right eye, LE = left eye.
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of six base pairs (CCCAGA) led to the putative inclusion of two amino
acids, aspartic acid and proline, in the olfactomedin-like domain
between the second and third bases of residue 396 (p.D395_
E396insDP) of myocilin. The sequence of the protein remains the
same, except for these two residues, causing an increase in the total
number of amino acids in the mutated myocilin from 504 to 506 res-
idues. The mutation is also present in an unaffected member of the
family (V-1), who is only nine years old. The new variation was pub-
lished in themyocilin variation database (www.myocilin.com; Hewitt
et al., 2008).
3.3. In silico analyses
From the alignment of normal human myocilin and myocilins from
other organisms: common chimpanzee, crab-eating macaque, greater
galago, brown rat, house mouse, domestic cat, domestic dog, cow,
horse, wild boar, European rabbit, Tasmanian devil, chicken andFig. 2. Direct sequencing of the third exon of the MYOC gene. In A, above — an unaffected su
showing the mutation c.1187_1188insCCCAGA in heterozygosis. The arrow indicates the lo
shown in red are the nucleotides and respective residues inserted.zebraﬁsh (protein sequences were taken from GenBank), it is clear
that neither Asp395 nor Glu396 residues are highly conserved among
mammal species; however, they are located within a conserved region
(Fig. 3). Molecular modeling resulted in a model structure for myocilin
olfactomedin-like domain which was predominantly composed by
antiparallel β-sheets, turns and disordered loops (Fig. 4). Although the
mutation does not truncate the protein, it might affect the pre-
existing secondary structure (according to the prediction program
PSIPRED v2.6). However, therewas no evident perturbation of the over-
all structure visible in the modeled mutant since the RMSD (root–
mean–square deviation) with wild type modeled structure was only
1.1 Å.
According to themodeled structure of p.D395_E396insDP, this inser-
tion caused reduction of accessible surface area of both Asp395 and
Glu396 (from 46.6 Å2 and 65.8 Å2 to 15.1 Å2 and 49.3 Å2, respectively).
Locally, there was an evident reduction of solvent exposed area built by
charged and polar groups (74.7 Å2 and 47.4 Å2 of reduced exposed
area, respectively), mainly from Gln368 and Glu357 which are locatedbject, with the wild type sequence of the MYOC gene, and below — an affected subject,
cation of the insertion. In B, the wild type and mutant cDNA and protein sequences,
Fig. 3. Multiple amino acid alignment of myocilin proteins, demonstrating that D395 and E396 are not highly conserved residues.
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sible to visualize that a neutral region emerged in the mutated struc-
ture, as indicated by a black arrow in the electrostatic surface maps of
wild type and mutant olfactomedin-like domains (Fig. 5A and B). The
neutral electrostatic potential may indicate that more charged groups
have been buried than exposed when aspartic acid and proline were
inserted. This can affect the balance of charges at the surface, and it
has been suggested that reduction of the net charge is signiﬁcantly asso-
ciated with protein deposition diseases (Chiti et al., 2002). According to
themodeledwild type structure the insertion site is located near anoth-
er important residue, P370, a mutation associated with JOAG (yellow
circle, Fig. 5A). The distance between P370 and the insertion site is
around 8 Å. In order to check if other mutations (reported in the litera-
ture) created a similar patch of neutral electrostatic surfaces, themolec-
ular structure of the JOAG-associatedmutation P370Lwasmodeled. The
mutated residue, leucine, is amore hydrophobic residue and it assumed
a position where it was exposed to a solvent at the protein surface.
His366 and Tyr365 became more exposed upon mutation (with addi-
tional 11.5 Å2 and 23.1 Å2 surface areas, respectively). The neutral
patch of the protein surface was slightly larger in the mutant than in
the wild type although smaller than the observed for the mutant
p.D395_E396insDP (Fig. 5C).
Since the reduced exposition to solvent of charged and polar resi-
dues at p.D395_E396insDP might indicate that neutral patches at theFig. 4. Overall structure ofmodeled olfactomedin domain ofmyocilin (residues 235–504)
shown in sticks are the residues associated with the disease.surface may have been formed, it is possible that these patches could
be also more hydrophobic. The Surface Hydrophobicity Index (SHI)
(Neshich et al., unpublished), based on Engelman scale, was calculat-
ed for the three modeled structures. The calculation of SHI is based on
normalization of each amino acid residue hydropathy by their effec-
tive accessible surface area. The SHI describes the cumulative surface
hydrophobicity for a selected chain. For wild type, SHI was 0.28,
smaller than the values obtained for the insertion mutant and P370L
mutant (0.288 and 0.283). An increased hydrophobic patch at this
protein may serve as target for binding to other mutated myocilin
proteins or to any other protein. It is known that low solubility and
aggregation of proteins are caused by increased area of exposed hy-
drophobic surfaces (Horwich, 2002). Even among variants which dis-
play similar structures, the aggregation propensity can be explained
by increased area of hydrophobic patches (Münch and Bertolotti,
2010).
The mutation may have also caused alterations of the internal con-
tact networks of olfactomedin-like domain such as the overall number
of charge repulsive contacts (from 13 in thewild type to 5 in themutant
model) which can also inﬂuence the protein function (Münch and
Bertolotti, 2010). Several alterations in the mutated protein can be ob-
served when comparing internal contacts (Fig. 6). In the wild type
myocilin, the Thr394 residue interacts with Ala400 and Tyr376 by
main-chain hydrogen bond and in the mutated protein, this residue
keeps the hydrogen bond with Ala402 (in wild type myocilin,
Ala400), but changes its interaction with Tyr376 to hydrophobic inter-
action. In addition, Thr394 also starts to interact hydrophobically with
Lys400 and Gly401 by side-chain hydrogen bond. The residue Asp395
interacts by one main-chain hydrogen bond type with Lys400 and two
main-chain hydrogen bonds with Ala399 in the normal myocilin. In
the mutant myocilin, Asp395 preserves the interaction with Lys402
and loses it with Ala401. At the same time it interacts with Glu398 by
main-chain hydrogen bond and with Pro397 (an inserted residue in
the mutation) hydrophobically. In the wild type protein, the residue
Glu396 interacts with Trp373 by main-chain hydrogen bond, with
Glu323 by charge repulsive interaction, with Lys398 bymain-chain hy-
drogen bond and two charge attractive interactions, and with Arg296
by two charge attractive interactions. However, in themutant myocilin,
Glu398maintains only themain-chain hydrogen bondwith Lys400 and
establishes a new interactionwith Gln368 by side-chain hydrogen bond
and with Ala402, Gly401, Asp396 (an inserted residue in the mutation)
and Asp395 by main-chain hydrogen bond. The residue Ala397 inter-
acts with Gly399 by main-chain hydrogen bond and with Asp395 by
side-chain and main-chain hydrogen bonds in the wild type myocilin.
Nevertheless, in the mutant protein, only the interaction by hydrogen
bond between Ala399 and Gly401 is maintained, and the new interac-
tion is established by main-chain hydrogen bond between Ala399 and
Fig. 5. Electrostatic potential surface map generated by PyMol for the modeled Olfactomedin domain of wild type myocilin (A) and the mutants p.D395_E396insDP (B) and p.P370L
(C). The black circle indicates the position of p.D395_E396insDP insertion and the yellow circle indicates the position of p.P370L mutation. Black arrow indicates the neutral surface
patch created upon mutations. Green and cyan arrows indicate position of Gln368 and Glu357, respectively.
55C.A. Braghini et al. / Gene 523 (2013) 50–57Asp396 (an inserted residue in the mutation). Furthermore, the
inserted residues increase the number of total interactions made by
the mutated protein. The inserted residue Ala396 makes contact with
Ala399, Glu398, and Trp373 by main-chain hydrogen bond and with
Lys400 by two charge attractive interactions. Pro397, the other residue
inserted in the mutation p.D395_E396insDP, makes contacts with
Asp395 and Ser372 by hydrophobic interaction. Thus in total, the wild
type myocilin makes 10 hydrogen bonds, two charge attractive and
one charge repulsive interaction, while the mutant protein makes 15
hydrogen bonds, two charge attractive and ﬁve hydrophobic
interactions.Fig. 6. Graphic of myocilin internal contacts generated by the STING Millennium Graphical
ﬂank the mutation in wild type (A) and mutant myocilin (B), as well as the contacts made4. Discussion
A novel mutation in the MYOC gene was reported that segregates
with JOAG in a Brazilian family. It is an in-frame mutation, c.1187_
1188insCCCAGA (p.D395_E396insDP), which leads to the insertion of
six base pairs between the second and third bases of codon 396.
Among disease-causingmutations categorized by type, small insertions
comprise only 5.3% of the total variants reported (www.myocilin.com;
Hewitt et al., 2008), and the c.1187_1188insCCCAGA insertion is proba-
bly involved in JOAG etiology in this family. This mutation does not
change the myocilin sequence, except for the insertion of two residues,Contacts program, showing the contacts made by the four residues (T, D, E and A) that
by the residues inserted (C). In D, the color legend of the contacts.
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stop codon is not created by the insertion, suggesting the gain of func-
tion as a mechanism in glaucoma associated with the MYOC gene,
which is the result of an abnormal property of mutant myocilin (Joe et
al., 2003). Despite of the fact that residues Asp395 and Glu396 are not
highly conserved among examined species, the mutation location is
close to conserved regions among myocilin orthologs, and therefore,
the insertion of the Asp and Pro residues might have caused signiﬁcant
changes in the mutated protein.
Structural modeling was performed using both threading and
restraint-based molecular homology modeling. The modeling proce-
dure was guided by threading suggestion and literature data. Recent
circular dichroism results indicate that olfactomedin domain is com-
posed mostly by antiparallel β-sheets and that there was no evidence
for α-helices (Orwig and Lieberman, 2011). This is in disagreement
with the myocilin model previously proposed in Kanagavalli et al.'s
(2003) study. At the same time, this experimental evidence corrobo-
rates with the model proposed in the present work, indicating that it
might be a better approximation to the real structure of myocilin
olfactomedin-like domain. It is also possible that misfunction of
myocilin protein is achieved by destabilization of internal contacts
imposed by the mutation. Considering only the four residues that
ﬂank the insertion site, and inserted residues, there is a considerable
difference between the internal contacts of the wild type and mutat-
ed protein. The increased number of hydrogen bonds and hydropho-
bic interactions may have caused changes not only in the mutation
site, but in other locations of the mutated protein.
The p.D395_E396insDP results in the inclusion of Asp396 andGlu397
in the protein sequence. Structural analysis demonstrated that the
in-frame insertion of two amino acids in the myocilin caused burial of
charged and polar groupswhichmay result in the exposition of a neutral
patch on the surface of the olfactomedin domain. According to modeled
structures, it is also possible that therewas an increase in the surface hy-
drophobicity, favoring not only interactions with other proteins and
myocilin itself but also aggregation.Another interesting feature observed
was the reduced number of charge-repulsive contacts (from 13 in wild
type to 5 in the insertion mutant), which may also account for
misfunction and aggregation propensity (Münch and Bertolotti, 2010).
Gobeil et al. (2006) investigated the secretion status of the
myocilin protein for 36 variants previously described in the MYOC
gene. The authors observed that 20 mutations disturb myocilin secre-
tion, and all of them encoded disease-causing proteins and carried
mutations within the olfactomedin-like domain, including the
p.396INS397 (www.myocilin.com; Hewitt et al., 2008) a duplication
of three base pairs (c.1886_1888dup) that occurs very close to the
mutation reported in the present study. According to those data, we
can infer that the myocilin with p.D395_E396insDP mutation may
have functional effect similar to those associated with the develop-
ment of glaucoma, retained in the ER. Further functional studies
would reveal if this mutation, such as many others in the MYOC
gene (e.g., p.Q368X, p.P370L, p.K423E, p.C433R, and p.396INS397),
leads to the intracellular sequestration (in the ER of trabecular mesh-
work cells) of insoluble aggregates of misfolded mutant myocilin,
causing the death of these cells, and therefore impairing the aqueous
humor outﬂow (Fautsch and Johnson, 2001; Jacobson et al., 2001).
About 8%–36% of JOAG cases and 3%–4% of adult-onset POAG cases
are carriers of missense mutations in the MYOC gene (Fingert, 2011).
Several investigations established good phenotype/genotype correla-
tions for MYOC mutations. In the Brazilian population, the most com-
mon mutation is p.C433R, which is associated with severe glaucoma,
including high penetrance before 40 years of age and IOP above
30 mmHg, as well as the frequent need for surgical intervention to
control the disease progression. The age of onset in carriers of this
mutation ranges from 17 to 58 years (Vasconcellos et al., 2003). The
most commonmutation in some populations, p.Q368X, has been asso-
ciated with mean IOP of about 20–30 mmHg and the patients werediagnosed with OAG at an older adult age (www.myocilin.com;
Hewitt et al., 2008). In the studied pedigree, we observed a milder
phenotype of JOAG compared to other reported cases, as the carriers
of p.P370L or p.Y437L mutations exhibited the early-onset form of
the disease (in the ﬁrst or second decades of life) andmeanmaximum
IOP over 40 mmHg (Shimizu et al., 2000; Wiggs et al., 1998).
In our study, we observed complete penetrance after 30 years of
age, with mean disease onset of 25 years (ranging from 20 to 30).
Three of the four affected members had high IOP (28 to 47 mmHg)
and a high cup-to-disc ratio (0.7 to 1.0), two are legally blind, and
the other has a severe form of glaucoma with important visual ﬁeld
defects, which jeopardized the central vision at 23 years of age. The
remaining member has a maximum IOP of 22 and 23 and cup-to-
disc ratios of 0.2 and 0.3 in the RE and LE, respectively. There is an un-
affected member of nine years old carrying the mutation and does not
exhibit any symptoms of glaucoma. If he has no adequate clinical
follow-up, this individual is at risk of developing glaucoma at a youn-
ger age. The lack of data about the structure of the myocilin protein
increases the importance of functional studies as well as genotype–
phenotype correlations, contributing to the knowledge of the role of
theMYOC gene in glaucoma. In addition, in the translational medicine
era, this study may help in the early diagnosis and proper assistance
of other members within this family, as well as increasing the panel
of MYOC mutations and their effects on phenotype.
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